Skip to main content
Moshe Talpaz, MD, Oncology, Ann Arbor, MI, University of Michigan Medical Center

MosheTalpazMD

Oncology • Ann Arbor, MI

Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Talpaz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Talpaz's full profile

Already have an account?

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981
  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1979 - 1980
  • The Hebrew University of Jerusalem Hadassah Medical School
    The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1971

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1981 - 2025
  • MI State Medical License
    MI State Medical License 2005 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors  
    Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
  • Leukemia Inhibitory Factor Functions in Parallel with Interleukin-6 to Promote Ovarian Cancer Growth  
    Karen McLean, Ronald J Buckanovich, Moshe Talpaz, Nature
  • The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid Leukemia  
    Dale L Bixby, Ivan P Maillard, Moshe Talpaz, Leukemia Research

Abstracts/Posters

  • Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis
    Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
    Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or...
    Moshe Talpaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Cen... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

  • The FOSSIL Study: FLAG or Standard 7+3 Induction Therapy in Secondary Acute Myeloid LeukemiaJune 2018

Press Mentions

  • How Useful Is Next-Generation Sequencing for Patients with Advanced Cancer?
    How Useful Is Next-Generation Sequencing for Patients with Advanced Cancer?March 12th, 2021
  • Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
    Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH MeetingDecember 6th, 2020
  • SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results
    SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial ResultsAugust 13th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Moshe Talpaz, Dr. Moshe Talpaz, MD, Dr. M Talpaz